Wockhardt Limited - Asset Resilience Ratio
Wockhardt Limited (WOCKPHARMA) has an Asset Resilience Ratio of 5.19% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2025)
This chart shows how Wockhardt Limited's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Wockhardt Limited to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Wockhardt Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Wockhardt Limited worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs4.22 Billion | 5.19% |
| Total Liquid Assets | Rs4.22 Billion | 5.19% |
Asset Resilience Insights
- Limited Liquidity: Wockhardt Limited maintains only 5.19% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Wockhardt Limited Industry Peers by Asset Resilience Ratio
Compare Wockhardt Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Almirall S.A.
MC:ALM |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 0.76% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
ANI Pharmaceuticals Inc
NASDAQ:ANIP |
Drug Manufacturers - Specialty & Generic | 0.63% |
|
Beijing Winsunny Pharmaceutical CO.LTD
SHG:601089 |
Drug Manufacturers - Specialty & Generic | 10.89% |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Annual Asset Resilience Ratio for Wockhardt Limited (2005–2025)
The table below shows the annual Asset Resilience Ratio data for Wockhardt Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 5.19% | Rs4.22 Billion ≈ $45.64 Million |
Rs81.35 Billion ≈ $879.77 Million |
+4.98pp |
| 2024-03-31 | 0.21% | Rs160.00 Million ≈ $1.73 Million |
Rs76.49 Billion ≈ $827.21 Million |
-1.01pp |
| 2023-03-31 | 1.22% | Rs940.00 Million ≈ $10.17 Million |
Rs76.83 Billion ≈ $830.89 Million |
+1.11pp |
| 2022-03-31 | 0.11% | Rs90.00 Million ≈ $973.32K |
Rs82.43 Billion ≈ $891.45 Million |
+0.04pp |
| 2021-03-31 | 0.07% | Rs54.40 Million ≈ $588.32K |
Rs77.73 Billion ≈ $840.59 Million |
-0.49pp |
| 2020-03-31 | 0.56% | Rs457.30 Million ≈ $4.95 Million |
Rs81.79 Billion ≈ $884.52 Million |
-0.92pp |
| 2019-03-31 | 1.48% | Rs1.16 Billion ≈ $12.54 Million |
Rs78.31 Billion ≈ $846.90 Million |
-3.42pp |
| 2018-03-31 | 4.90% | Rs4.00 Billion ≈ $43.26 Million |
Rs81.62 Billion ≈ $882.69 Million |
-13.38pp |
| 2017-03-31 | 18.28% | Rs16.39 Billion ≈ $177.29 Million |
Rs89.69 Billion ≈ $969.93 Million |
+8.10pp |
| 2016-03-31 | 10.18% | Rs8.10 Billion ≈ $87.56 Million |
Rs79.52 Billion ≈ $860.00 Million |
+4.34pp |
| 2015-03-31 | 5.85% | Rs4.06 Billion ≈ $43.87 Million |
Rs69.39 Billion ≈ $750.41 Million |
-3.13pp |
| 2014-03-31 | 8.97% | Rs5.94 Billion ≈ $64.26 Million |
Rs66.22 Billion ≈ $716.15 Million |
+8.97pp |
| 2013-03-31 | 0.00% | Rs2.70 Million ≈ $29.20K |
Rs60.40 Billion ≈ $653.21 Million |
-4.60pp |
| 2011-03-31 | 4.61% | Rs2.71 Billion ≈ $29.34 Million |
Rs58.89 Billion ≈ $636.83 Million |
-3.87pp |
| 2010-03-31 | 8.48% | Rs4.85 Billion ≈ $52.50 Million |
Rs57.26 Billion ≈ $619.21 Million |
-0.89pp |
| 2009-03-31 | 9.37% | Rs6.31 Billion ≈ $68.20 Million |
Rs67.28 Billion ≈ $727.62 Million |
+5.71pp |
| 2008-03-31 | 3.66% | Rs1.89 Billion ≈ $20.42 Million |
Rs51.53 Billion ≈ $557.29 Million |
-33.74pp |
| 2005-03-31 | 37.41% | Rs7.18 Billion ≈ $77.63 Million |
Rs19.19 Billion ≈ $207.51 Million |
-- |
About Wockhardt Limited
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH… Read more